

OMB APPROVAL	
OMB Number:	3235-0167
Expires:	November 30, 2010
Estimated average burden hours per response	1.50

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 15**

**Certification and Notice of Termination of Registration under Section 12(g) of the  
Securities Exchange Act of 1934 or Suspension of Duty to File Reports Under Sections 13  
and 15(d) of the Securities Exchange Act of 1934**

Commission File Number 001-13341

**Titan Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

**400 Oyster Point Blvd., Suite 505, South San Francisco, CA 94080 (650) 244-4990**

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

**Common Stock**

(Title of each class of securities covered by this Form)

**N/A**

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1) <input checked="" type="checkbox"/>	Rule 12h-3(b)(1)(ii) <input type="checkbox"/>
Rule 12g-4(a)(2) <input type="checkbox"/>	Rule 15d-6 <input type="checkbox"/>
Rule 12h-3(b)(1)(i) <input type="checkbox"/>	

Approximate number of holders of record as of the certification or notice date: 143

Pursuant to the requirements of the Securities Exchange Act of 1934 Titan Pharmaceuticals, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Date: December 15, 2008

By: /s/ Robert Farrell

Robert Farrell, Chief Financial Officer

Instruction: This form is required by Rules 12g-4, 12-h-3 and 15d-6 of the General Rules and Regulations under the Securities Exchange Act of 1934. The registrant shall file with the Commission three copies of Form 15, one of which shall be manually signed. It may be signed by an officer of the registrant, by counsel or by any other duly authorized person. The name and title of the person signing the firm shall be typed or printed under the signature.

SEC2069(02-08)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**